First Human Receives Age Reversal Injection in Groundbreaking Trial

Medical Milestone Reached

For the first time in human history, doctors have injected a patient with a treatment designed to reverse cellular aging. Life Biosciences announced on June 9, 2026, that it dosed the first patient in its Phase 1 trial of ER-100, marking a pivotal moment in the quest to turn back the biological clock.

The injection went into one eyeball of a single person with glaucoma , targeting vision loss caused by age-related damage to the optic nerve. Life Biosciences, cofounded by Harvard geneticist David Sinclair, received FDA approval for the first human trial testing partial epigenetic reprogramming to restore vision in patients with glaucoma and NAION . The Boston-based company beat well-funded competitors including Altos Labs and Retro Biosciences backed by tech titans Jeff Bezos and Sam Altman .

Life Biosciences is the first to test this in humans, with a little under 20 patients slated to participate in the initial FDA trial . The treatment represents the first ever cellular rejuvenation therapy using epigenetic reprogramming to receive FDA clearance to enter human clinical trials .

How the Technology Works

ER-100 originated from Life Bio's Partial Epigenetic Reprogramming (PER) platform, which aims to restore aged or injured cells to a younger state by modifying the epigenome of cells, biochemical markers that regulate gene expression without altering the underlying DNA sequence . The approach uses three of the four Yamanaka factors, the transcription factors OCT-4, SOX-2, and KLF-4 (OSK) .

The Phase 1 trial will inject viruses carrying three reprogramming genes directly into patients' eyes, with the treatment controlled by doxycycline antibiotic dosing over two months . Researchers plan to inject viruses carrying three powerful reprogramming genes directly into patients' eyes to deliver "rejuvenation instructions" to damaged retinal ganglion cells .

The technology has shown promise in animal studies. ER-100's story begins with highly successful experiments in rodents, where Sinclair's team used their own partial cellular reprogramming recipe to restore vision after a severe optic nerve injury, and then proceeded to a successful trial in non-human primates .

Risks and Concerns

Despite the breakthrough, researchers remain cautious about potential side effects. Cellular reprogramming has been linked to cancer in animal trials . The original story noted that two of the four proteins involved in the process have the potential to divide uncontrollably, and some mice developed tumors during testing.

The trial will target patients with glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), two conditions that can cause blindness through optic nerve damage . NAION is described as a "stroke of the eye" that can cause sudden blindness .

Future Implications

The potential for cellular reprogramming to reshape how doctors diagnose and treat disease is massive. If cells can be re-engineered to perform better as we age, there are applications well beyond better eyesight and stronger muscles . The therapies could, one day, extend healthy life .

Because it's a gene therapy, researchers will enroll patient number one, wait 28 days, then enroll patients two and three, wait another 28 days. Then they'll make decisions about going up and down on the dose . The careful, methodical approach reflects both the promise and the responsibility that comes with testing humanity's first age-reversal therapy.

The company hopes to eventually expand beyond eye treatments. The original research suggests future applications could include liver and muscle cell rejuvenation, potentially addressing multiple age-related diseases at their cellular source.